Dr Spira on the Ongoing PACIFIC-8 Trial in Unresectable Stage III NSCLC
June 30th 2023
Alexander I. Spira, MD, PhD, FACP, discusses the ongoing phase 3 PACIFIC-8 trial of durvalumab in combination with domvanalimab following concurrent chemoradiotherapy in patients with unresectable stage III non–small cell lung cancer.